PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells. 2021

Wei Liu, and Chunyu Wang, and Shengli Wang, and Kai Zeng, and Shan Wei, and Ning Sun, and Ge Sun, and Manlin Wang, and Renlong Zou, and Wensu Liu, and Lin Lin, and Huijuan Song, and Zining Jin, and Yue Zhao
Department of Cell Biology, Key laboratory of Cell Biology, Ministry of Public Health, and Key laboratory of Medical Cell Biology, Ministry of Education, School of Life Sciences, China Medical University, Shenyang City, Liaoning Province110122, China.

Androgen receptor (AR) and its variants play vital roles in development and progression of prostate cancer. To clarify the mechanisms involved in the enhancement of their actions would be crucial for understanding the process in prostate cancer and castration-resistant prostate cancer transformation. Here, we provided the evidence to show that pre-mRNA processing factor 6 (PRPF6) acts as a key regulator for action of both AR full length (AR-FL) and AR variant 7 (AR-V7), thereby participating in the enhancement of AR-FL and AR-V7-induced transactivation in prostate cancer. In addition, PRPF6 is recruited to cis-regulatory elements in AR target genes and associates with JMJD1A to enhance AR-induced transactivation. PRPF6 also promotes expression of AR-FL and AR-V7. Moreover, PRPF6 depletion reduces tumor growth in prostate cancer-derived cell lines and results in significant suppression of xenograft tumors even under castration condition in mouse model. Furthermore, PRPF6 is obviously highly expressed in human prostate cancer samples. Collectively, our results suggest PRPF6 is involved in enhancement of oncogenic AR signaling, which support a previously unknown role of PRPF6 during progression of prostate cancer and castration-resistant prostate cancers.

UI MeSH Term Description Entries
D008297 Male Males
D011944 Receptors, Androgen Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA. Androgen Receptors,5 alpha-Dihydrotestosterone Receptor,Androgen Receptor,Dihydrotestosterone Receptors,Receptor, Testosterone,Receptors, Androgens,Receptors, Dihydrotestosterone,Receptors, Stanolone,Stanolone Receptor,Testosterone Receptor,5 alpha Dihydrotestosterone Receptor,Androgens Receptors,Receptor, 5 alpha-Dihydrotestosterone,Receptor, Androgen,Receptor, Stanolone,Stanolone Receptors,alpha-Dihydrotestosterone Receptor, 5
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072260 RNA Splicing Factors RNA-binding proteins that facilitate or inhibit RNA SPLICING. Splicing Factor,Splicing Factors,Factor, Splicing,Factors, RNA Splicing,Factors, Splicing,Splicing Factors, RNA
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D015533 Transcriptional Activation Processes that stimulate the GENETIC TRANSCRIPTION of a gene or set of genes. Gene Activation,Genetic Induction,Transactivation,Induction, Genetic,Trans-Activation, Genetic,Transcription Activation,Activation, Gene,Activation, Transcription,Activation, Transcriptional,Genetic Trans-Activation,Trans Activation, Genetic
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D056484 Jumonji Domain-Containing Histone Demethylases A family of histone demethylases that share a conserved Jumonji C domain. The enzymes function via an iron-dependent dioxygenase mechanism that couples the conversion of 2-oxoglutarate to succinate to the hydroxylation of N-methyl groups. JmjC Domain-Containing Histone Demethylases,JmjC Domain Containing Histone Demethylases,Jumonji Domain Containing Histone Demethylases
D064129 Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE. Androgen-Independent Prostatic Cancer,Androgen-Independent Prostatic Neoplasms,Androgen-Insensitive Prostatic Cancer,Androgen-Insensitive Prostatic Neoplasms,Androgen-Resistant Prostatic Cancer,Androgen-Resistant Prostatic Neoplasms,Castration-Resistant Prostatic Cancer,Castration-Resistant Prostatic Neoplasms,Hormone Refractory Prostatic Cancer,Hormone Refractory Prostatic Neoplasms,Prostatic Cancer, Androgen-Independent,Prostatic Cancer, Androgen-Insensitive,Prostatic Cancer, Androgen-Resistant,Prostatic Cancer, Castration-Resistant,Prostatic Cancer, Hormone Refractory,Prostatic Neoplasms, Androgen-Independent,Prostatic Neoplasms, Androgen-Insensitive,Prostatic Neoplasms, Androgen-Resistant,Prostatic Neoplasms, Hormone Refractory,Androgen Independent Prostatic Cancer,Androgen Independent Prostatic Neoplasms,Androgen Insensitive Prostatic Cancer,Androgen Insensitive Prostatic Neoplasms,Androgen Resistant Prostatic Cancer,Androgen Resistant Prostatic Neoplasms,Androgen-Independent Prostatic Cancers,Androgen-Independent Prostatic Neoplasm,Androgen-Insensitive Prostatic Cancers,Androgen-Insensitive Prostatic Neoplasm,Androgen-Resistant Prostatic Cancers,Androgen-Resistant Prostatic Neoplasm,Cancer, Androgen-Independent Prostatic,Cancer, Androgen-Insensitive Prostatic,Cancer, Androgen-Resistant Prostatic,Cancer, Castration-Resistant Prostatic,Cancers, Androgen-Independent Prostatic,Cancers, Androgen-Insensitive Prostatic,Cancers, Androgen-Resistant Prostatic,Cancers, Castration-Resistant Prostatic,Castration Resistant Prostatic Cancer,Castration Resistant Prostatic Neoplasms,Castration-Resistant Prostatic Cancers,Castration-Resistant Prostatic Neoplasm,Neoplasm, Androgen-Independent Prostatic,Neoplasm, Androgen-Insensitive Prostatic,Neoplasm, Androgen-Resistant Prostatic,Neoplasm, Castration-Resistant Prostatic,Neoplasms, Androgen-Independent Prostatic,Neoplasms, Androgen-Insensitive Prostatic,Neoplasms, Androgen-Resistant Prostatic,Neoplasms, Castration-Resistant Prostatic,Prostatic Cancer, Androgen Independent,Prostatic Cancer, Androgen Insensitive,Prostatic Cancer, Androgen Resistant,Prostatic Cancer, Castration Resistant,Prostatic Cancers, Androgen-Independent,Prostatic Cancers, Androgen-Insensitive,Prostatic Cancers, Androgen-Resistant,Prostatic Cancers, Castration-Resistant,Prostatic Neoplasm, Androgen-Independent,Prostatic Neoplasm, Androgen-Insensitive,Prostatic Neoplasm, Androgen-Resistant,Prostatic Neoplasm, Castration-Resistant,Prostatic Neoplasms, Androgen Independent,Prostatic Neoplasms, Androgen Insensitive,Prostatic Neoplasms, Androgen Resistant,Prostatic Neoplasms, Castration Resistant

Related Publications

Wei Liu, and Chunyu Wang, and Shengli Wang, and Kai Zeng, and Shan Wei, and Ning Sun, and Ge Sun, and Manlin Wang, and Renlong Zou, and Wensu Liu, and Lin Lin, and Huijuan Song, and Zining Jin, and Yue Zhao
August 2016, International journal of urology : official journal of the Japanese Urological Association,
Wei Liu, and Chunyu Wang, and Shengli Wang, and Kai Zeng, and Shan Wei, and Ning Sun, and Ge Sun, and Manlin Wang, and Renlong Zou, and Wensu Liu, and Lin Lin, and Huijuan Song, and Zining Jin, and Yue Zhao
January 2023, Frontiers in pharmacology,
Wei Liu, and Chunyu Wang, and Shengli Wang, and Kai Zeng, and Shan Wei, and Ning Sun, and Ge Sun, and Manlin Wang, and Renlong Zou, and Wensu Liu, and Lin Lin, and Huijuan Song, and Zining Jin, and Yue Zhao
August 2016, International journal of urology : official journal of the Japanese Urological Association,
Wei Liu, and Chunyu Wang, and Shengli Wang, and Kai Zeng, and Shan Wei, and Ning Sun, and Ge Sun, and Manlin Wang, and Renlong Zou, and Wensu Liu, and Lin Lin, and Huijuan Song, and Zining Jin, and Yue Zhao
February 2015, Expert review of anticancer therapy,
Wei Liu, and Chunyu Wang, and Shengli Wang, and Kai Zeng, and Shan Wei, and Ning Sun, and Ge Sun, and Manlin Wang, and Renlong Zou, and Wensu Liu, and Lin Lin, and Huijuan Song, and Zining Jin, and Yue Zhao
January 2023, Frontiers in oncology,
Wei Liu, and Chunyu Wang, and Shengli Wang, and Kai Zeng, and Shan Wei, and Ning Sun, and Ge Sun, and Manlin Wang, and Renlong Zou, and Wensu Liu, and Lin Lin, and Huijuan Song, and Zining Jin, and Yue Zhao
December 2019, Annals of translational medicine,
Wei Liu, and Chunyu Wang, and Shengli Wang, and Kai Zeng, and Shan Wei, and Ning Sun, and Ge Sun, and Manlin Wang, and Renlong Zou, and Wensu Liu, and Lin Lin, and Huijuan Song, and Zining Jin, and Yue Zhao
January 2019, The Journal of clinical investigation,
Wei Liu, and Chunyu Wang, and Shengli Wang, and Kai Zeng, and Shan Wei, and Ning Sun, and Ge Sun, and Manlin Wang, and Renlong Zou, and Wensu Liu, and Lin Lin, and Huijuan Song, and Zining Jin, and Yue Zhao
September 2022, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Wei Liu, and Chunyu Wang, and Shengli Wang, and Kai Zeng, and Shan Wei, and Ning Sun, and Ge Sun, and Manlin Wang, and Renlong Zou, and Wensu Liu, and Lin Lin, and Huijuan Song, and Zining Jin, and Yue Zhao
January 2013, Cancer journal (Sudbury, Mass.),
Wei Liu, and Chunyu Wang, and Shengli Wang, and Kai Zeng, and Shan Wei, and Ning Sun, and Ge Sun, and Manlin Wang, and Renlong Zou, and Wensu Liu, and Lin Lin, and Huijuan Song, and Zining Jin, and Yue Zhao
May 2023, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!